Histopathological assessment of inflammation and expression of inflammatory markers in patients with ketamine-induced cystitis

HSIN-CHUNG LIN¹, HERNG-SHENG LEE¹, TZONG-SHI CHIUEH³, YU-CHIEH LIN¹,², HSIN-AN LIN³,⁴, YU-CHUN LIN¹, TAI-LUNG CHA⁵ and EN MENG⁵

¹Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490; ²Department of Pathology, Taoyuan Armed Forces General Hospital, Taoyuan 32551; ³Division of Infection, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490; ⁴Division of Infection, Department of Medicine, Tri-Service General Hospital SongShan Branch, Taipei 10581; ⁵Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan, R.O.C.

Received January 9, 2014; Accepted October 24, 2014

DOI: 10.3892/mmr.2014.3110

Abstract. The aim of the current study was to evaluate the histopathological features of inflammation and the expression levels of inflammatory markers in tissue samples from patients with ketamine-induced cystitis. Bladder biopsy samples for histological analysis were obtained from 23 patients (18 men and 5 women) with a self-reported history of ketamine use and who were treated for cystitis at the Tri-Service General Hospital of Taipei, Taiwan. Immunohistochemical staining for cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), matrix metalloproteinase-9 (MMP-9), mammalian target of rapamycin (mTOR), and phosphorylated 40S ribosomal protein S6 (Phos-S6) was performed. The results revealed urothelial atypia in all patients, and intravascular eosinophil accumulation in 22 patients. Histopathological features included denuded urothelial mucosa, ulceration, collagen deposition, smooth muscle degeneration and vessel proliferation. Tissue samples were immunopositive for all of the inflammation markers, including the urothelium, vessel walls, and smooth muscle. COX-2 staining revealed a significant difference between the inflammatory levels in the urothelium and smooth muscle, and iNOS staining differed significantly between inflammatory levels in smooth muscle (p=0.029). A positive correlation was observed between the percentage of Phos-S6-positive cells and the levels of inflammation in the urothelium. These results add to the descriptive literature on the histopathologic aspects of ketamine-induced cystitis, emphasizing the inflammatory nature and a possible role for proteins such as COX-2, iNOS and Phos-S6 in the degree of inflammation.

Introduction

Ketamine is a phencyclidine derivative first used as an intravenous anesthetic agent in 1965 (1) and approved by the US Food and Drug Administration in 1970 for use in producing analgesia and amnesia, with rapid recovery (2,3). It is predominantly an N-methyl-D-aspartate (NMDA) receptor antagonist, producing a state that is similar to catalepsy, termed dissociative anesthesia, in which sensory inputs appear to reach the cortical sensory areas but are not perceived, owing to suppression of association areas (4). In addition, ketamine affects non-NMDA glutamine receptors, as well as opioid, nicotinic, monoaminergic and muscarinic cholinergic receptors (5). While it is used medically as an anesthetic agent, the use of ketamine as a recreational drug in Taiwan has increased over the last 10 years, and it is emerging as an increasingly popular choice among young drug users, particularly in dance clubs (6,7). There is a prevailing misconception among this population that as a short-acting psychotropic agent, ketamine is not as harmful as other drugs, for example heroin, and that it has a broad margin of safety and a low potential for dependence. However, it has been reported that the majority of ketamine abusers (79%) display features of physiological dependence following a year of regular ketamine abuse, and 54% reported withdrawal symptoms on termination of use (8).

Ketamine abuse can also lead to severe lower urinary tract symptoms, complicated by decreased bladder capacity and hematuria. Ketamine-associated cystitis was first reported in case reports by Chu et al (9) and Shahani et al (10) in 2007 and was recently comprehensively reviewed by Wei et al (11). While the incidence of ketamine-associated lower urinary tract symptoms is difficult to assess, it is thought to be at least 30% among abusers (12). It has been suggested that the presence of ketamine and its active metabolites, including norketamine and dehydronorketamine, in the urine may damage the urinary tract mucosa (10). A recent study in rats reported that ketamine treatment results in bladder hyperactivity, along with ulcerated...
urothelium and mononuclear cell infiltration (13). These alterations were accompanied by significant increases in the expression levels of cyclooxygenase-2 (COX-2) and two nitric oxide synthase (NOS) isoforms [inducible NOS (iNOS) and endothelial NOS (eNOS)], which were determined by western blot analysis, in addition to a significant increase in the number of COX-2-positive cells, as determined by immunohistochemistry (13). The authors suggested that these pathological changes, together with the upregulation of inflammatory proteins, may have an important role in ketamine-induced ulcerative cystitis in rats. The aim of the present study was to assess the histopathological features and the degree of inflammation in the bladder urothelium, vessel walls, and smooth muscle of patients with ketamine-induced cystitis, to determine if the expression levels of inflammatory markers, such as those described above (13), had correlated with the degree of inflammation.

Materials and methods

Patients and sample collection. This study was approved by the Institutional Review Board of the Tri-Service General Hospital (Taipei, Taiwan). A total of 23 patients at the Tri-Service General Hospital with a self-reported history of ketamine abuse and a confirmed diagnosis of cystitis were included in this retrospective study. Each patient presented with lower urinary tract symptoms such as urgency, nocturia and frequency. Urine and blood samples were collected from each patient for analysis. The urine test panel included pH, occult blood, acetonuria, urea, uric acid, bilirubin, protein, creatinine, urinalysis (WBCs, RBCs, nitrite, pH, specific gravity, color and sediment), and urine protein, bilirubin, urobilinogen, ketones, acetone, glucose, ketamine abuse and a confirmed diagnosis of cystitis were evident in association with urothelial ulceration. Normal cells scattered throughout the tissue but background stromal connective tissue clearly visible; severe inflammation, mononuclear inflammatory cells densely infiltrating the tissues. The degree of inflammation in each case was assessed throughout the specimen. Although lymphoid follicles with germinal centers were encountered, these were not assessed.

Immunohistochemical staining. Paraffinized sections (0.6 μm) were generated for immunohistochemistry from patients (3-10 sections/patient) with sufficient specimens from the urothelial biopsy. When >1 block was available, we used the same block used for histopathologic diagnosis. Sections were mounted on silanized glass slides, stored in the dark at 58°C, and subjected to immunohistochemical analysis within 1 week. Following paraffin removal and rehydration, the sections were subjected to antigen retrieval by microwave heating in 10 mM citrate buffer, pH 6.0 (Merck Eurolab, Copenhagen, Denmark) twice, for 5 min each time. Endogenous peroxidase activity was blocked by incubation in 5% H2O2 in distilled water for 20 min at room temperature, followed by 30 min incubation at room temperature with primary antibodies targeting COX-2 (monoclonal, anti-mouse; Thermo Labsystems, Santa Rosa, CA, USA), iNOS (monoclonal, anti-mouse; Thermo Labsystems), and matrix metalloproteinase-9 (MMP-9; monoclonal, anti-mouse; Abcam, Cambridge, UK) (14), as well as cancer-related markers, including mammalian target of rapamycin (mTOR; monoclonal, anti-mouse; Thermo, Rockford, IL, USA) and phosphorylated 40S ribosomal protein S6 (Phos-S6; monoclonal, anti-mouse; Immunotech, Marseille, France). All of the antibodies were diluted to 1:200 in antibody diluent (Dako, Glostrup, Denmark) (15-17). Sections were subsequently incubated with secondary antibody [EnVision™ FLEX/HRP + Rabbit/Mouse (LINKER)] for 20 min at room temperature. Intervening washes were performed in EnVision FLEX wash buffer for 5 min each. For COX-2, antigen-antibody complex was visualized with 3,3’-diaminobenzidine (EnVision FLEX DAB + Chromogen). For iNOS, MMP-9, mTOR and Phos-S6, the antigen-antibody complex was visualized using the 3-amino-9-ethylcarbazole (AEC) color system (MUTO), and sections were counterstained with Mayer’s hematoxylin (MUTO). The stained sections without primary antibodies were used as a negative control. Slides were coverslipped with Glycergel Mounting Medium (Dako) and examined under an Olympus BX51 light microscope in a double-blind manner by two histopathologists. The staining intensity of the urothelium, vessel walls and smooth muscle was scored as follows: 0, no staining; 1, mild staining; 2, moderate staining; 3, intense staining. In addition the percentage of positive cells within a 10 x 10 cm grid (area, 0.25 mm2; magnification, x200) was calculated (18). The percentage of positive cells was counted regardless of staining intensity.

Assessment of inflammation. Paraffinized sections (0.6 μm) from each patient (3-10 sections/patient) were stained with Gill’s hematoxylin V (MUTO, Tokyo, Japan) and 1% eosin alcohol solution (MUTO; H&E). The degree of inflammation was assessed according to a semi-quantitative scale. H&E-stained slides were examined under light microscopy (Olympus BX51; Olympus, Tokyo, Japan) in a double-blind manner by two histopathologists. Inflammation was scored as follows: mild inflammation, <5 mononuclear inflammatory cells in a 10x10 grid (area, 0.25 mm2; magnification, x200); moderate inflammation, mononuclear inflammatory cells scattered throughout the tissue but background stromal connective tissue clearly visible; severe inflammation, mononuclear inflammatory cells densely infiltrating the tissues. The degree of inflammation in each case was assessed throughout the specimen. Although lymphoid follicles with germinal centers were encountered, these were not assessed.

Statistical analysis. Statistical analysis was performed using SPSS statistics software version 15.0 (SPSS, Inc., Chicago, IL, USA). The patient demographic and clinical characteristics are presented as the mean ± standard deviation (SD) for continuous data and n (%) for categorical data. Morphological data are presented as n (%) by inflammatory stage. The differences among the inflammatory stages were compared using Fisher’s exact test. Spearman correlation analysis was
performed to identify correlations between the morphologic data and inflammatory stage. Results are presented as the coefficient of correlation (r) and the corresponding P-value. Statistical assessments were two-tailed and significance was set at P<0.05.

Results

A total of 23 subjects (18 males and 5 females) were analyzed in this study. Demographic and clinical characteristics are summarized in Table I. The average age was 21.8±3.7 years (mean ± SD). Duration of ketamine usage ranged from 2 to 6 years, however, there were 12 patients for whom this information was not available. The morphology of the bladder in ketamine-induced cystitis was highlighted by staining with H&E, as shown in Fig. 1. Mucosal histologic features of ketamine-associated cystitis included the following in variable numbers of patients (Fig. 1): denuded urothelial mucosa with a thinner layer of epithelial cells, ulceration, changes in clarity, increased collagen deposition, smooth muscle degeneration in the stromal tissue, vessel proliferation, calcification, and inflammation with variable numbers of neutrophils, eosinophils, and mast cells. Inflammation was mild for 2 patients (8.7%), moderate for 15 (65.2%) and severe for 6 (26.1%). All of the patients received a diagnosis of urothelial atypia, and the majority (22/23) showed intravascular eosinophil accumulation. In addition, lymphatic duct proliferation was noted in only one patient.

Urine analysis. Seven patients showed no protein in the urine, two showed equivocal results, five showed 1+ proteinuria, eight showed 2+, and one showed 3+. Only one patient had urine bilirubin. The urine pH range was 5.5-7.5. Testing for occult blood was negative in seven patients, equivocal in two, 1+ in one, 2+ in three, and 3+ in ten. The results of testing for RBCs were <10 in nine patients, 10-100 in four and >100 in ten. The results of testing for WBCs were <10 in 13 patients, 10 to 100 in seven, and >100 in three. Testing for bacteria was negative in 17 patients, equivocal in one, 1+ in three and 2+ in two.

Blood analysis leukocytosis was present in three patients, and six were anemic. All 23 patients had a normal platelet range. Four patients showed neutrophilia, one showed neutropenia, and seven showed lymphocytopenia. Five patients showed an increase in the levels of monocytes, and one showed a decrease in the levels of monocytes. One patient showed eosinophilia.

Immunohistochemical staining for inflammation markers. Immunostaining in tissues with different degrees of inflammation (mild, moderate and severe) revealed staining for all five of the inflammation markers (Fig. 2). Quantification of the immunohistochemical staining of sections from certain patients is presented in Tables II and III. Table II displays immunohistochemical staining intensity (0-3) by inflammation level (mild, moderate and severe) in the urothelium, vessel walls, and smooth muscle. COX-2 staining differed significantly between the degrees of inflammation (mild, moderate and severe) in the urothelium and smooth muscle (P=0.027 urothelium; P=0.020 smooth muscle). In the urothelium, for example, only one specimen stained 3+ and one specimen stained 2+ for COX-2 in the tissue with mild inflammation. However, all four specimens from the tissue with severe inflammation stained 3+ for COX-2 (Table II). In addition, iNOS staining differed significantly between the degrees of inflammation in smooth muscle (P=0.029). No significant difference was found between the degrees of inflammation for MMP-9, Phos-S6 or mTOR staining.

Table III shows the percentage of immunostaining positive cells by degree of inflammation. Results of the Spearman
Figure 1. Morphology of the urinary bladder in ketamine-induced cystitis. Urothelial mucosa in ketamine-induced cystitis stained with hematoxylin and eosin demonstrating (A) denuded, (B) ulcerated, (C) clear change with a suburothelial blister and (D) urothelial nuclear atypical morphologies. The stroma of the urinary bladder revealed (A) collagen deposition, (E) intravascular eosinophils accumulation, (F) smooth muscle degeneration and (G) calcification. In addition, (G) lymphatic duct proliferation was noted in only one patient. (magnification, x200).

Figure 2. Immunohistochemical staining of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), matrix metalloproteinase-9 (MMP-9), mammalian target of rapamycin (mTOR) and phosphorylated 40S ribosomal protein S6 (Phos-S6) in the urothelium with different degrees of inflammation (magnification, x200).
Table II. Immunostaining for inflammation markers and histologic assessment of inflammation in the urothelium, vessel wall and smooth muscle.

| Staining intensity<sup>a</sup> | No. of samples<sup>b</sup> | Urothelium | Vessel wall | Smooth muscle |
|------------------------------|---------------------------|------------|-------------|---------------|
|                              | Mild (n=2) | Moderate (n=15) | Severe (n=6) | P-value | Mild (n=2) | Moderate (n=15) | Severe (n=6) | P-value | Mild (n=2) | Moderate (n=15) | Severe (n=6) | P-value |
| COX-2                      |            |              |              |        |            |              |              |        |            |              |              |        |
| 0                           | 0          | 0           | 0           | 0      | 0          | 0           | 0           | 0      | 0          | 0           | 0           | 0      |
| 1                           | 1          | 1           | 1           | 0      | 1          | 1           | 1           | 0      | 1          | 1           | 1           | 1      |
| 2                           | 6          | 1           | 5           | 0      | 4          | 0           | 3           | 1      | 6          | 1           | 1           | 4      |
| 3                           | 6          | 1           | 1           | 4      | 8          | 1           | 4           | 3      | 8          | 1           | 7           | 0      |
| MMP-9                      |            |              |              |        |            |              |              |        |            |              |              |        |
| 0                           | 0          | 0           | 0           | 0      | 0          | 0           | 0           | 0      | 0          | 0           | 0           | 0      |
| 1                           | 4          | 1           | 2           | 1      | 0          | 0           | 0           | 0      | 3          | 0           | 1           | 2      |
| 2                           | 2          | 0           | 2           | 0      | 6          | 1           | 2           | 3      | 9          | 1           | 5           | 3      |
| 3                           | 9          | 0           | 6           | 3      | 14         | 1           | 10          | 3      | 7          | 1           | 6           | 0      |
| iNOS                       |            |              |              |        |            |              |              |        |            |              |              |        |
| 0                           | 0          | 0           | 0           | 0      | 3          | 1           | 2           | 0      | 3          | 1           | 1           | 1      |
| 1                           | 0          | 0           | 0           | 0      | 4          | 0           | 2           | 2      | 8          | 0           | 3           | 5      |
| 2                           | 2          | 0           | 2           | 0      | 4          | 0           | 2           | 2      | 7          | 1           | 6           | 0      |
| 3                           | 11         | 2           | 5           | 4      | 7          | 1           | 4           | 2      | 0          | 0           | 0           | 0      |
| Phos-S6                     |            |              |              |        |            |              |              |        |            |              |              |        |
| 0                           | 0          | 0           | 0           | 0      | 2          | 1           | 1           | 0      | 6          | 1           | 4           | 1      |
| 1                           | 2          | 1           | 1           | 0      | 0          | 0           | 0           | 0      | 3          | 1           | 0           | 2      |
| 2                           | 5          | 1           | 4           | 0      | 7          | 1           | 4           | 2      | 3          | 0           | 2           | 1      |
| 3                           | 5          | 0           | 2           | 3      | 4          | 0           | 2           | 2      | 0          | 0           | 0           | 0      |
| mTOR                       |            |              |              |        |            |              |              |        |            |              |              |        |
| 0                           | 0          | 0           | 0           | 0      | 2          | 1           | 1           | 0      | 0          | 0           | 0           | 0      |
| 1                           | 1          | 0           | 1           | 0      | 4          | 0           | 3           | 1      | 1          | 0           | 1           | 0      |
| 2                           | 5          | 1           | 2           | 2      | 5          | 1           | 2           | 2      | 5          | 0           | 2           | 3      |
| 3                           | 1          | 0           | 0           | 1      | 3          | 0           | 1           | 2      | 6          | 1           | 3           | 2      |

<sup>a</sup>Staining intensity: 0, no staining; 1, mild staining; 2, moderate staining; 3, intense staining. <sup>b</sup>Samples were not obtained for all 23 patients. Data are presented as n (%). Differences among inflammation levels were compared by the Fisher's exact test. <sup>c</sup>P<0.05 and <sup>d</sup>P<0.01 dispersion of immunohistochemical staining intensity between mild, moderate and severe inflammation status, by pairwise comparison. COX-2, cyclooxygenase-2; iNOS, inducible nitric oxide synthase; MMP-9, matrix metallopeptidase-9; mTOR, mammalian target of rapamycin; Phos-S6, phosphorylated 40S ribosomal protein S6.
Table III. Percentage of cells immunopositive for inflammation markers and histologic assessment of inflammation in the urothelium, vessel wall and smooth muscle.

| Marker | Inflammation | Urothelium | Vessel wall | Smooth muscle |
|--------|--------------|------------|-------------|---------------|
|        | No. of samples<sup>a</sup> | % Positive cells<sup>b</sup> | r-value<sup>c</sup> | P-value | No. of samples<sup>a</sup> | % Positive cells<sup>b</sup> | r-value<sup>c</sup> | P-value | No. of samples<sup>a</sup> | % Positive cells<sup>b</sup> | r-value<sup>c</sup> | P-value |
| COX-2  |              |            |            |           |              |            |            |           |              |            |            |           |
| Mild  | 2            | 80.0       | 0.194      | 0.526     | 2            | 40.0       | 0.049      | 0.851     | 2            | 50.0       | -0.088     | 0.736     |
| Moderate | 7            | 61.4       |            |           | 10           | 52.0       |            |           | 9            | 47.8       |            |           |
| Severe | 4            | 80.0       |            |           | 5            | 48.0       |            |           | 6            | 41.7       |            |           |
| MMP-9  |              |            | 0.209      | 0.454     |              | -0.105     | 0.658      |           | 2            | 55.0       | 0.020      | 0.933     |
| Mild  | 1            | 90.0       |            |           | 2            | 45.0       |            |           | 2            | 55.0       |            |           |
| Moderate | 10           | 77.0       |            |           | 12           | 70.0       |            |           | 13           | 65.4       |            |           |
| Severe | 4            | 87.5       |            |           | 6            | 51.7       |            |           | 5            | 60.0       |            |           |
| iNOS   |              |            | 0.315      | 0.295     |              | 0.159      | 0.572      |           | 2            | 40.0       | -0.002     | 0.994     |
| Mild  | 2            | 85.0       |            |           | 1            | 30.0       |            |           | 2            | 40.0       |            |           |
| Moderate | 7            | 74.3       |            |           | 8            | 50.0       |            |           | 10           | 39.0       |            |           |
| Severe | 4            | 87.5       |            |           | 6            | 51.7       |            |           | 5            | 36.0       |            |           |
| Phos-S6 |              |            | 0.815      | 0.001<sup>d</sup> |              | 0.286      | 0.394      |           | 1            | 10.0       | 0.112      | 0.833     |
| Mild  | 2            | 20.0       |            |           | 4            | 67.5       |            |           | 1            | 10.0       |            |           |
| Moderate | 7            | 50.0       |            |           | 1            | 60.0       |            |           | 2            | 25.0       |            |           |
| Severe | 3            | 83.3       |            |           | 6            | 53.3       |            |           | 3            | 20.0       |            |           |
| mTOR   |              |            | 0.250      | 0.588     |              | -0.263     | 0.409      |           | 1            | 30.0       | 0.020      | 0.951     |
| Mild  | 1            | 30.0       |            |           | 1            | 70.0       |            |           | 1            | 30.0       |            |           |
| Moderate | 2            | 60.0       |            |           | 6            | 70.0       |            |           | 6            | 41.7       |            |           |
| Severe | 4            | 65.0       |            |           | 5            | 46.0       |            |           | 5            | 39.0       |            |           |

<sup>a</sup>Samples were not obtained for all 23 patients. <sup>b</sup>Data are presented as the mean. <sup>c</sup>Coefficient of correlation (r) was derived by the Spearman correlation analysis. A positive r-value indicates a positive correlation, and a negative r-value indicates a negative correlation. <sup>d</sup>Significant correlation. COX-2, cyclooxygenase 2; iNOS, inducible nitric oxide synthase; MMP-9, matrix metallopeptidase-9; mTOR, mammalian target of rapamycin; Phos-S6, phosphorylated 40S ribosomal protein S6.
correlation analysis indicated a positive correlation between the percentage of Phos-S6-positive cells and the degree of inflammation in the urothelium (r=0.815; P=0.001) but no in other tissues. No section from normal tissue and negative control showed immunostaining positive cells.

Discussion

The aim of the present study was to evaluate the histopathological features and inflammation status of samples from patients with ketamine-induced cystitis to determine if markers of inflammation were expressed. The results revealed histopathological features consistent with those previously reported (7,9,10-12), including marked intravascular eosinophil accumulation and variable denuded urothelial mucosa and ulceration; the majority of patients (65.2%) showed moderate inflammation, with the remainder showing severe (26.1%) or mild (8.7%) inflammation. Samples showed positive immunostaining for all 5 of the inflammation markers assessed, with COX-2 staining differing significantly between the three degrees of inflammation in the urothelium and smooth muscle, and iNOS staining differing significantly with inflammation level in smooth muscle.

The mechanism of ketamine-induced ulcerative cystitis remains to be elucidated. Results from animal models (13) and the pathological data of the current study suggest that the urothelium may play a role in the pathogenesis of ketamine-induced cystitis. The etiology of ketamine-induced cystitis may be the direct toxic effect of ketamine and its active metabolite on the bladder mucosa (7). Ketamine induces significant submucosal hemorrhage, enhanced macrophage infiltration, ulceration, reduced urothelium thickness and the degeneration of smooth muscle. These pathological changes may be the cause of the ketamine-induced expression of COX-2, iNOS and MMP-9 in the urothelium, vessel wall and smooth muscle. The present results, along with those in rats (13), suggest that inflammatory markers, including COX-2 and iNOS, may be involved, either as a result of ketamine-induced cystitis or inducing it. Notably, an increase in the expression of COX-2 and iNOS has been reported in response to cyclophosphamide-induced cystitis in rats (19,20). Matrix metalloproteinase (MMP)-2 and MMP-9, collectively known as the gelatinases, are closely associated with inflammatory and infectious diseases in a number of organs (21). However, the current study did not find a correlation between the MMP-9 expression and inflammation levels in tissues of ketamine-induced cystitis.

Notably, the histopathological features of ketamine-induced cystitis in this study showed a marked intravascular eosinophil accumulation, suggesting that the inflammatory response may begin from the blood vessels in the bladder. However, significant differences in the COX-2 and iNOS staining intensity as well as % immunostaining positive cells were not observed between tissues from three degrees of inflammation. It has been suggested that other inflammatory mediators induced by ketamine may be involved in the induction of intravascular eosinophil accumulation.

The results of the present study indicated a positive correlation between the percentage of Phos-S6-positive cells and inflammation level in the urothelium. The expression of mTOR and mTOR pathway members, such as Phos-S6, have been reported in bladder carcinoma (15-17,22). Oxley et al (23) have reported that ketamine-induced cystitis is a mimic of carcinoma in situ. The results of the current study confirmed their observations that the markers of bladder carcinoma may be observed in the tissues of patients with ketamine-induced cystitis. However, it is unclear at this time why there was a positive correlation between the percentage of Phos-S6-positive cells in the urothelium and the degree of inflammation.

Limitations of the present retrospective study include the fact that no samples were analyzed from control subjects (e.g. non-ulcerative cystitis or healthy tissues from non-abusers) due to the ethical reasons, and the fact that immunohistochemical staining was not performed for all subjects. In addition this study did not assess the ketamine level in urine samples, or the association between duration of ketamine usage and severity of ulcerative cystitis (severity of inflammation). The latter information was not available for 12 subjects. In conclusion, these results add to the descriptive literature on histopathologic aspects of ketamine-induced cystitis, emphasizing the inflammatory nature and a possible role for proteins such as COX-2, iNOS and Phos-S6. Ketamine and its active metabolites may have a direct toxic effect on the bladder mucosa; the observed histopathologic changes may induce or increase expression of COX-2, iNOS and Phos-S6 in the urothelium and smooth muscle.

Acknowledgements

This study was supported by a grant from Tri-Service General Hospital, Taiwan, Republic of China (grant nos. TSGH-C100-145, TSGH-C101-059, TSGH-C102-056 and TSGH-C102-159).

References

1. Domino EF, Chodoff P and Corssen G: Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6: 279-291, 1965.
2. Sehdev RS, Symmons DA and Kindl K: Ketamine for rapid sequence induction in patients with head injury in the emergency department. Emerg Med Australas 18: 37-44, 2006.
3. Craven R: Ketamine. Anaesthesia 62: 48-53, 2007.
4. Bhutta AT: Ketamine: a controversial drug for neonates. Semin Perinatol 31: 303-308, 2007.
5. Corsen G and Domino EF: Dissociative anaesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 45: 29-40, 1966.
6. Lankenau SE and Sanders B: Patterns of ketamine use among young injection drug users. J Psychoactive Drugs 39: 21-29, 2007.
7. Chen CH, Lee MH, Chen YC and Lin MF: Ketamine-shortening associated cystitis. J Formos Med Assoc 110: 787-791, 2011.
8. Chen R, Lee AM and Chan R: A study on the cognitive impairment and other harmful effects from ecstasy and ketamine abuse. In: Hong Kong Chinese 2004. Narcotics Division, Security Bureau. The Government of the Hong Kong Special Administrative Region, 2004 (http://www.nd.gov.hk/pdf/Study%20on%the%20Cognitive%20Impairment%20and%20Other%20Harmful%20Effects%20Caused%20by%20Ketamine%20Abuse.pdf).
9. Chu PS, Kwok SC, Lam KM, et al: 'Street ketamine'-associated bladder dysfunction: a report of ten cases. Hong Kong Med J 13: 311-313, 2007.
10. Shahani R, Streutker C, Dickson B and Stewart RJ: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007.
11. Wei YB, Yang JR, Yin Z, Guo Q, Liang BL and Zhou KQ: Genitourinary toxicity of ketamine. Hong Kong Med J 19: 341-348, 2013.
12. Chu PS, Ma WK, Wong SC, et al: The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 102: 1616-1622, 2008.
13. Chuang SM, Liu KM, Li YL, et al: Dual involvements of cyclooxygenase and nitric oxide synthase expressions in ketamine-induced ulcerative cystitis in rat bladder. Neurourol Urodyn 32: 1137-1143, 2013.
14. Mohammed MA, Seleim MF, Abdalla MS, Sharada HM and Abdel Wahab AH: Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol 13: 25, 2013.
15. Schultz L, Chaux A, Albadine R, et al: Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 35: 1549-1556, 2011.
16. Hansel DE, Platt E, Orloff M, et al: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176: 3062-3072, 2010.
17. Makhlin I, Zhang J, Long CJ, et al: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 108: E84-E90, 2011.
18. Sappayatosok K, Maneerat Y, Swasdison S, et al: Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinic-pathological correlation. Med Oral Patol Oral Cir Bucal 14: E319-E324, 2009.
19. Hu VY, Malley S, Dattilio A, Folsom JB, Zvara P and Vizzard MA: COX-2 and prostanooids expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol 284: R574-R585, 2003.
20. Xue X, Cubeddu LX and Malave A: Expression of inducible nitric oxide synthase in primary culture of rat bladder smooth muscle cells by plasma from cyclophosphamide-treated rats. Eur J Pharmacol 416: 1-9, 2001.
21. Chakrabarti S and Patel KD: Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 31: 599-621, 2005.
22. Chaux A, Compérat E, Varinot J, et al: High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection. Urology 81: 116-122, 2013.
23. Oxley JD, Cottrell AM, Adams S and Gillatt D: Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 55: 705-708, 2009.